Skip to main navigation Skip to search Skip to main content

Immunomodulation as a Protective Strategy in Chronic Otitis Media

Anke Leichtle*, Arwa Kurabi, David Leffers, Markus Därr, Clara Sophia Draf, Allen Frederic Ryan, Karl Ludwig Bruchhage

*Corresponding author for this work

Abstract

Introduction: Major features of the pathogenesis in otitis media, the most common disease in childhood, include hyperplasia of the middle ear mucosa and infiltration by leukocytes, both of which typically resolve upon bacterial clearance via apoptosis. Activation of innate immune receptors during the inflammatory process leads to the activation of intracellular transcription factors (such as NF-κB, AP-1), which regulate both the inflammatory response and tissue growth. We investigated these leading signaling pathways in otitis media using mouse models, human samples, and human middle ear epithelial cell (HMEEC) lines for therapeutic immunomodulation. Methods: A stable otitis media model in wild-type mice and immunodeficient KO-mice, as well as human tissue samples from chronic otitis media, skin from the external auditory canal and middle ear mucosa removed from patients undergoing ear surgery, were studied. Gene and protein expression of innate immune signaling molecules were evaluated using microarray, qPCR and IHC. In situ apoptosis detection determined the apoptotic rate. The influence of bacterial infection on immunomodulating molecules (TNFα, MDP, Tri-DAP, SB203580, Cycloheximide) in HMEEC was evaluated. HMEEC cells were examined after bacterial stimulation/inhibition for gene expression and cellular growth. Results: Persistent mucosal hyperplasia of the middle ear mucosa in chronic otitis media resulted from gene and protein expression of inflammatory and apoptotic genes, including NODs, TNFα, Casp3 and cleaved Casp3. In clinical chronic middle ear samples, these molecules were modulated after a specific stimulation. They also induced a hyposensitive response after bacterial/NOD-/TLR-pathway double stimulation of HMEEC cells in vitro. Hence, they might be suitable targets for immunological therapeutic approaches. Conclusion: Uncontrolled middle ear mucosal hyperplasia is triggered by TLRs/NLRs immunoreceptor activation of downstream inflammatory and apoptotic molecules.

Original languageEnglish
Article number826192
JournalFrontiers in Cellular and Infection Microbiology
Volume12
DOIs
Publication statusPublished - 30.03.2022

Funding

This work was supported by Grant E37-2010 (AL) University of Lübeck, the NIH Grant DC000129, and the VA Research Service-Grant 1BX001205 (AR), and NIH Grant DC014801 (AK). We would like to thank Sylvia Grammerstorf, Ralph Pries (Department of Otorhinolaryngology, Lübeck, Germany) for excellent technical support and Jan Rupp (Department of Infectious Diseases and Microbiology, University of Lübeck, Germany) for supporting the bacterial and cell experiments; as well as the late Dr. David J. Lim (University of California, Los Angeles (UCLA)) for providing the human middle ear epithelial cell line (HMEEC) used in this study.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Immunomodulation as a Protective Strategy in Chronic Otitis Media'. Together they form a unique fingerprint.

Cite this